Enhancement of opiate binding by various molecular forms of phosphatidylserine and inhibition by other unsaturated lipids.
A study was undertaken on the possible involvement of phospholipids on stereospecific opiate binding to a rat brain membrane fraction comprised mainly of synaptic membranes. The addition of acidic phospholipids such as phosphatidylserine, phosphoinositides, and phosphatidic acid significantly enhanced opiate binding. With the exception of phosphatidylserine, when the acidic phospholipids contained a polyunsaturated acyl group, they were actually inhibitory, along with neutral phospholipids derived from brain. Both the C18:0, C18:1 form (derived from myelin) and the C18:0, C22:6 form of phosphatidylserine (derived from synaptic membranes) produced as much as a 45% enhancement in opiate binding. Unsaturated fatty acids were highly inhibitory, the degree of inhibition being related to the degree of unsaturation. Both phospholipase A and C were inhibitory; and the inhibitory effect of A could not be prevented by albumin or overcome with the addition of phosphatidylserine. With the use of the cross-linking agent, dinitrodifluorobenzene, it could be demonstrated that the phosphatidylserine of synaptic membranes appeared to be preferentially associated with membrane protein. The enhancement of opiate binding by phosphatidylserine diminished with increasing degree of cross-linking.
D000818:Animals; D001921:Brain / Q000378:metabolism*; D004139:Dinitrofluorobenzene / Q000494:pharmacology; D004091:Hydromorphone / Q000378:metabolism*; D010718:Phosphatidylserines / Q000378:metabolism*; D010743:Phospholipids / Q000494:pharmacology*; D051381:Rats; D011957:Receptors, Opioid; D013329:Structure-Activity Relationship; D013570:Synaptic Membranes / Q000187:drug effects / Q000378:metabolism
D010718:Phosphatidylserines; D010743:Phospholipids; D011957:Receptors, Opioid; D004139:Dinitrofluorobenzene; D004091:Hydromorphone